Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II study
✍ Scribed by A. Figueredo; A. Arnold; M. Goodyear; B. Findlay; A. Neville; R. Normandeau; A. Jones
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 806 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract In an attempt to develop more effective chemotherapy regimens in advanced nonsmall cell lung cancer (NSCLC), we evaluated docetaxel‐ifosfamide‐cisplatin (DIP) based on our previous experience with paclitaxel‐ifosfamide‐cisplatin. Patients with advanced NSCLC (stages III‐IV), WHO‐PS≤2, n
## Abstract The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received
## Abstract A phase II trial of etoposide and cisplatin for patients with previously treated small cell lung cancer was carried out by CALGB from June 1983 to May 1984. Thirty‐five evaluable patients who had failed one prior chemotherapy regimen were treated with etoposide 80 mg/m^2^ and cisplatin